Table 2.
Characteristics (demographics and comorbidity) at the start of therapy with generic or brand-name statin
| Group | Brand-name | Generic | Total | p |
|---|---|---|---|---|
| Number of patients (%) | 3007 (22.7%) | 10,237 (77.3%) | 13,244 (100%) | |
| Sociodemographic characteristics | ||||
| Average age (years) | 61.4 (11.7) | 61.2 (11.3) | 61.3 (11.4) | 0.501 |
| Ranges: | ||||
| 18–44 years | 7.2% | 7.7% | 7.6% | |
| 45–64 years | 52.9% | 51.9% | 52.1% | |
| 65–74 years | 23.0% | 25.9% | 25.2% | |
| ≥ 75 years | 16.8% | 14.6% | 15.1% | 0.234 |
| Sex (female) | 52.7% | 52.5% | 52.6% | 0.827 |
| Pensioners | 50.2% | 51.6% | 50.5% | 0.191 |
| General comorbidity | ||||
| Average diagnoses | 6.6 (3.6) | 6.5 (3.3) | 6.5 (3.3) | 0.502 |
| Charlson index | 0.7 (1.0) | 0.7 (1.0) | 0.7 (1.0) | 0.855 |
| Average RUB | 2.9 (0.7) | 3.0 (0.7) | 3.0 (0.7) | 0.527 |
| 1 (very low comorbidity) | 3.9% | 3.4% | 3.5% | |
| 2 (low comorbidity) | 15.4% | 14.8% | 14.9% | |
| 3 (moderate comorbidity) | 65.5% | 66.7% | 66.4% | |
| 4 (high comorbidity) | 13.2% | 13.2% | 13.2% | |
| 5 (very high comorbidity) | 2.1% | 1.9% | 1.9% | |
| Associated comorbidities | ||||
| Hypertension | 50.2% | 51.6% | 50.5% | 0.191 |
| Diabetes mellitus | 22.8% | 23.0% | 22.9% | 0.786 |
| Obesity | 19.4% | 19.8% | 19.5% | 0.658 |
| Active smokers | 24.0% | 22.9% | 23.7% | 0.224 |
| Alcoholism | 3.5% | 4.2% | 3.7% | 0.064 |
| Ischemic heart disease | 8.3% | 9.4% | 8.5% | 0.057 |
| Cerebrovascular accident | 11.0% | 9.9% | 10.8% | 0.091 |
| Previous cardiovascular event | 19.0% | 18.3% | 18.8% | 0.382 |
| Organ failure | 17.3% | 17.7% | 17.4% | 0.675 |
| Dementia | 2.4% | 2.5% | 2.5% | 0.792 |
| Depressive syndrome | 21.5% | 21.4% | 21.5% | 0.182 |
| Malignant neoplasms | 9.4% | 9.0% | 9.3% | 0.537 |
Values expressed as percentage or mean (standard deviation), p statistical significance between brand-name vs. generic, RUB resource utilization band